N-Terminal pro-brain natriuretic peptide levels and abnormal geometric patterns of left ventricle in untreated hypertensive patients

Clinical and Experimental Hypertension

Volumn 36, Issue 3, 2014, Pages 153-158

  Elbasan, Zafer ^a   Gür, Mustafa ^a   Şahin, Durmuş Yildiray ^a   Kirim, Sinan ^a   Akyol, Selahattin ^a   Kuloǧlu, Osman ^a   Koyunsever, Nermin Yildiz ^a   Şeker, Taner ^a   Kivrak, Ali ^a   Çayli, Murat ^a  

^a Numune Training and Research Hospital   (Turkey)

Author keywords

BNP; Ejection fraction; Geometry; Hypertension; Hypertrophy

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; BLOOD; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; VENTRICULAR FUNCTION, LEFT;

EID: 84898483077     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2013.804538     Document Type: Article

References (24)

1. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9-13.
2. Irzmański R, Pawlicki L, Charłusz M, Kowalski J. Concentration of natriuretic peptides in patients suffering from idiopathic arterial hypertension and left ventricular diastolic dysfunction confirmed by echocardiography. Clin Exp Hypertens 2012;34:530-40.
3. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46:660-6.
4. Olsen MH, Wachtell K, Tuxen C, et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004;22:1597-604.
5. McKie PM, Rodeheffer RJ, Cataliotti A, et al. Amino-terminal pro-B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006; 47:874-80.
6. Paget V, Legedz L, Gaudebout N, et al. N-terminal pro-brain natriuretic peptide: a powerful predictor of mortality in hypertension. Hypertension 2011;57:702-9.
7. Koren M J, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114: 345-52.
8. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992;19:1550-8.
9. Krauser DG, Devereux RB. Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz 2006;31:305-16.
10. Luchner A, Burnett Jr JC, Jougasaki M, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000;18:1121-8.
11. Hedvig J, Podracká L, Potoceková D. Elevated brain natriuretic peptide is associated with abnormal heart geometry in children with chronic kidney disease. Kidney Blood Press Res 2010;33:87-93.
12. Kosmala W, Spring A. Plasma levels of atrial and brain natriuretic peptide and left ventricular geometry in patients with essential hypertension. Pol Merkur Lekarski 2003;14:216-19.
13. Irzmański R, Banach M, Piechota M, et al. Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters. Clin Exp Hypertens 2007;29:149-64.
14. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28:22-30.
15. Lang RM, Bierig M, Devereux RB, et al; Chamber Quantification Writing Group. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-63.
16. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiog-raphy. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
17. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-18.
18. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 2003;21:1011-53.
19. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
20. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002;44:293-321.
21. Hildebrandt P, Boesen M, Olsen M, et al. N-terminal pro brain natriuretic peptide in arterial hypertension a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004;6: 313-17.
22. Roselló-Llet́i E, Calabuig JR, Morillas P, et al. Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study. PLoS One 2012;7:e31189 (1-9).
23. Masugata H, Senda S, Murao K, et al. Association between echocardiographic parameters and brain natriuretic peptide levels in treated hypertensive patients. Clin Exp Hypertens 2011;33: 187-91.
24. Sayama H, Nakamura Y, Saito N, et al. Relationship between left ventricular geometry and brain natriuretic peptide levels in elderly subjects. Gerontology 2000;46:71-7.